We Said These 4 Dividend Aristocrats Could Soar. Here’s How They Did, Plus 3 New Picks.

About a twelvemonth ago, 24/7 Wall St. flagged 4 overlooked Dividend Aristocrats arsenic stealth maturation plays, arguing that boring income names carried existent upside if the marketplace ever noticed. The scorecard is in, and it is divided down the middle. Two of the 4 bushed the marketplace decisively, portion the different 2 lagged. Below is simply a candid grading of the archetypal quartet, positive 3 caller Aristocrat-caliber income names wherever the setup looks compelling now.

Becton Dickinson: A Late Rally Salvages the Call

Becton Dickinson (NYSE:BDX) was the toughest telephone of the archetypal four, and it yet worked. Shares gained 25.5% successful the past twelvemonth and are up 17.47% twelvemonth to day aft a 9.1% one-week popular to $176.86.

The dividend motor inactive hums. Becton Dickinson pays a quarterly $1.05, with an annualized guardant payout of $4.20, and the existent output is 2.4% against a guardant P/E of 13. Coverage is not an issue: year-to-date escaped currency travel of $1.73 billion, up 44.6% twelvemonth implicit year, comfortably funds the payout, and absorption raised FY26 adjusted EPS guidance to $12.62 to $12.72. The main hazard is the tariff overhang and $450 cardinal successful non-cash impairment charges tied to strategical exits.

Grade: B+. A coagulated treble for income holders who reinvested.

SoFi Active Invest is offering a limited-time promotion. Open an account, money it with $50 oregon more, and you could person up to $3,000 successful complimentary banal for Active Invest accounts. See for yourself by clicking present now. (Sponsor)

AbbVie: The Home Run of the Group

AbbVie (NYSE:ABBV) was the star. Shares are up 47.4% implicit the trailing twelvemonth and 16.7% twelvemonth to date, closing astatine $246.04 connected August 7. The immunology franchise did precisely what bulls hoped, with Skyrizi +24.4% and Rinvoq +24.5% much than offsetting Humira's biosimilar-driven decline.

The dividend, presently $1.73 quarterly for an annualized guardant $6.92, keeps grinding higher, and the output stands astatine 2.8%. Safety metrics: escaped currency travel output of 4.10%, involvement sum of 6.94x, and nett debt/EBITDA of 2.26x. Q2 adjusted EPS of $3.65 bushed the statement estimation connected $16.99 cardinal successful revenue, +10.2% twelvemonth implicit year. The trailing P/E of 69 reflects dense amortization; the guardant EPS usher of $13.87 to $14.07 normalizes the aggregate considerably. Risk: continued Humira erosion and dilution from the $10.9 cardinal Apogee Therapeutics acquisition.